Clinical Trial Update: A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor. [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating MabThera (rituximab) in rheumatoid arthritis patients who had an inadequate response to a single anti-TNF inhibitor; the study status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• MabThera (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 4 | Status: COMPLETED